Sweden Tackles Economic Threat of Antibiotic Resistance with Updated National Action Plan

Antibiotic resistance is emerging as a major global health crisis with severe economic implications, prompting Sweden to update its national action plan as part of a 10-year strategy to combat antimicrobial resistance. According to the World Health Organization, one in six infections is now resistant to antibiotics, and projections warn of 39 million deaths in the next 25 years if no effective action is taken. Economically, antibiotic resistance could drive up global healthcare costs by $412 billion annually and cause production losses of $443 billion, potentially reducing global GDP by up to 3.8% by 2050, a blow comparable to the 2008 financial crisis.

The rise in antibiotic resistance is largely driven by misuse in healthcare and extensive use in agriculture, where 73% of medically important antibiotics are consumed by animal farming worldwide. This trend not only threatens the effectiveness of life-saving medical procedures such as surgeries, childbirth, and cancer treatments but also jeopardizes food security with global animal production expected to decline by up to 11%.

While Sweden's own antibiotic use remains low, the global nature of the issue means the country is not immune to these risks. Investors in Sweden are increasingly viewing antibiotic resistance as a systemic risk that permeates all sectors, impacting portfolios beyond traditional diversification methods. The societal costs will affect insurers, pension funds, and banks, potentially diminishing asset values.

In response, Swedish investors are encouraged to collaborate on aligning investment and antibiotic usage practices with long-term socio-economic sustainability goals, akin to ongoing efforts tackling climate change. Many investors are already working with organizations such as FAIRR and the Access to Medicine Foundation and are urged to join the global initiative Investor Action on AMR to enhance policy impact and capacity building.

This coordinated approach aims to ensure continued access to effective antibiotics worldwide, fostering economic stability and equity. As Sweden updates its national strategy, the involvement of investors highlights an innovative pledge to address this critical systemic risk comprehensively.